Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
A deeper-than-usual look at the pharmacology of GLP-1 receptor agonists — the receptor biology, the multi-organ distribution, and how that explains both the desired effects and the side-effect profile.
GLP-1 receptors (GLP-1R) are G-protein-coupled receptors expressed across multiple tissues: pancreatic alpha and beta cells, vagal afferent neurons, hypothalamus (especially arcuate nucleus), nucleus tractus solitarius, gastric smooth muscle, kidney, cardiac myocytes, and vascular endothelium. The widespread distribution explains why GLP-1 agonist effects extend beyond glycemia.
In pancreatic beta cells, GLP-1R activation enhances insulin secretion only when ambient glucose is elevated. The molecular mechanism: GLP-1R activation raises cAMP, which potentiates the closure of K-ATP channels (already closing in response to glucose). This is why GLP-1 agonists don't produce hypoglycemia on their own — they amplify a glucose-dependent process rather than triggering insulin release de novo.
In pancreatic alpha cells, GLP-1R activation suppresses glucagon secretion. The effect is also glucose-dependent — glucagon suppression is preserved during eu- or hyperglycemia, where it's beneficial, but does not fully suppress at low glucose, where glucagon's counter-regulatory action is protective.
Slowing gastric emptying contributes to both the glycemic effect (slower glucose entry into circulation) and the satiety effect (prolonged distension, vagal afferent signaling). The vagus nerve is a major route — vagal GLP-1R signaling carries the satiety signal to the brainstem (NTS).
Hypothalamic POMC neurons in the arcuate nucleus are stimulated; AgRP/NPY neurons are inhibited. Reward-system effects in the ventral tegmental area and nucleus accumbens reduce food reward responses. Patients describe these effects as "I just don't think about food the same way" and "my appetite is quieter." This is direct CNS pharmacology, not behavioral.
GLP-1R is expressed in vascular endothelium and cardiomyocytes. Direct effects include: improved endothelial function, reduced vascular inflammation, reduced atherosclerotic plaque progression, modest BP reduction (~3–5 mmHg systolic). These mechanisms contribute to the SELECT findings.
Direct effects on the kidney include reduced glomerular hyperfiltration, anti-inflammatory effects on renal interstitium, and indirect benefits via BP reduction and improved glycemia. These contribute to FLOW findings.
Tirzepatide activates both GLP-1R and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. The added GIP component likely explains tirzepatide's larger weight effect — the proposed mechanism involves adipose tissue effects mediated through GIP receptors, though the precise pharmacology is incompletely worked out.
Nausea, slowed gastric emptying, constipation, diarrhea: these are direct consequences of the same mechanisms that produce the beneficial effects. They are not separable. Tolerance develops over weeks; titration is built around this.
Native GLP-1 has a half-life of 1–2 minutes due to DPP-4 cleavage. Therapeutic GLP-1 agonists are engineered to resist DPP-4. Semaglutide adds a fatty acid side chain that binds albumin, extending half-life to ~7 days. Tirzepatide uses a similar approach with ~5-day half-life. Liraglutide's modification gives ~13-hour half-life (hence daily dosing).
See our research bibliography for primary pharmacology references.